Use

Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder characterized by muscle weakness, most commonly due to autoantibody-mediated loss of functional acetylcholine receptors (AChR) in the neuromuscular junction. AChR binding autoantibodies are diagnostic of MG and found in 85–90% of patients. AChR blocking autoantibodies prevent interaction of binding antibodies with the AChR. Fewer than 1% of patients have blocking antibodies without binding antibodies. Blocking antibodies are present in about 50% of MG patients but are rare in other conditions; thus, blocking antibodies can be useful in ruling out false positives in binding assays or detecting rare patients with blocking but not binding antibodies.